traitement martial du patient en insuffisance rénale chronique ...

More documents

Recommendations

Info

224 M. KESSLERDans une étude prospective longitudinale réalisée chez 123 patients suivispendant 1 an, nous avons montré que le taux de ferritine est élevé au moment dela greffe (407 ± 642 µg/l) et qu’il diminue de façon rapide pour atteindre 123 ±263 µg/l à 1 an, le taux d’Hb passant de 10,3 ± 2 à 12,3 ± 1,5 g/dl, ce qui suggèreune bonne utilisation du fer pour l’érythropoïèse [59]. La supplémentation martialedoit être faite avec précaution, en particulier au cours de la première année quisuit la greffe. L’apparition d’une carence martiale peut traduire une érythropoïèseaccélérée annonçant le développement d’une polyglobulie et dans ce cas l’administrationde fer peut aboutir à une augmentation explosive de l’hématocrite [60].Dans une étude prospective destinée à évaluer la prévalence de la polyglobuliesurvenant après transplantation rénale, nous avons montré que 44 p. 100 despatients devenus polyglobuliques avaient reçus du fer alors qu’aucun des patientsnormocythémiques n’en avaient reçu [61]. Nous suggérons donc de ne pas traiterune carence martiale apparaissant chez le transplanté lorsque le taux d’Hb augmentede façon régulière.BIBLIOGRAPHIE1. ESCHBACH JW. The anemia of chronic renal failure : pathophysiology and the effects of recombinanterythropoietin. Kidney Int, 1989, 35, 134-148.2. ESCHBACH JW, EGRIE JC, DOWNING MR et al. Correction of the anemia of end-stage renal diseasewith recombinant human erythropoietin : results of a combined phase I and phase II clinical trial.N Engl J Med, 1987, 316, 73-78.3. EDWARDS MS, PEGRUM GD, CURTIS JR. Iron therapy in patients on maintenance haemodialysis.Lancet, 1970, 5, 491-493.4. ESCHBACH JW, COOK JD, SCRIBNER BH et al. Iron balance in hemodialysis patients. Ann InternMed, 1977, 87, 710-713.5. FUDIN R, JAICHENKO J, SHOSTAK A et al. Correction of uremic iron deficiency anemia in hemodialyzedpatients : a prospective study. Nephron, 1998, 79, 299-305.6. FINCH CA, BELLOTI V, STRAY S et al. Plasma ferritin determination of a diagnostic tool. West JMed, 1986, 145, 657-663.7. MACDOUGALL IC, CAVILL I, HULME B et al. Detection of functional iron deficiency during erythropoietintreatment : a new approach. Br Med J, 1992, 304, 225-226.8. CAVILL I. Disorders of iron metabolism. Diagnostic methods. Clin Haematol, 1982, 11, 259-275.9. ROSENBERG ME. Role of transferrin measurement in monitoring iron status during recombinanthuman erythropoietin therapy. Dial Transplant, 1992, 2, 81-90.10. BRAUN J, LINDNER K, SCHREIBER M et al. Percentage of hypochromic red blood cells as a predictorof erythropoietic and iron response after IV iron supplementation in maintenance haemodialysispatients. Nephrol Dial Transplant, 1997, 12, 1173-1181.11. SCHAEFER RM, SCHAEFER L. The hypochronic red cell : a new parameter for monitoring of ironsupplementation during rhEPO therapy. J Perinat Med, 1995, 23, 83-88.12. FISHBANE S, SHAPIRO W, DUTKA P et al. A randomized trial of iron deficiency testing strategies inhemodialysis patients. Kidney Int, 2001, 60, 2406-2411.13. FISHBANE S, GALGANO C, LANGLEY RC et al. Reticulocytes hemoglobin content in the evaluationof iron status of hemodialysis patients. Kidney Int, 1997, 52, 217-222.14. MITTMAN N, SREEDHARA R, MUSHNISK R. Reticulocyte hemoglobin content predicts functionaliron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis, 1997, 30, 912-922.15. SILVA J, ANDRADE S, VENTURA H et al. Iron supplementation in haemodialysis. Practical clinicalguidelines. Nephrol Dial Transplant, 1998, 13, 2572-2577.
TRAITEMENT MARTIAL DU PATIENT EN INSUFFISANCE RÉNALE 22516. FISHBANE S, KOWALSKI EA, IMBRIANO LJ et al. The evaluation of iron status in hemodialysispatients. J Am Soc Nephrol, 1996, 7, 2654-2657.17. KAUFMAN JS, REDA JD, FYE CL et al. Diagnostic value of iron indices in hemodialysis patientsreceiving epoetin. Kidney Int, 2001, 60, 300-308.18. KALENTAR-ZADEH K, HOFFKEN B, WUNSCH H et al. Diagnosis of iron deficiency anemia in renalfailure patients during the post-erythropoietin era. Am J Kidney Dis, 1995, 26, 292-299.19. TESSITORE N, SOLERO GP, LIPPI G et al. The role of iron status markers in predicting response tointravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant,2001, 16, 1416-1423.20. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Nationalkidney foundation – dialysis outcomes quality intiative. Am J Kidney Dis, 1997, 4, S202-S212.21. European best practice guidelines for the management of anaemia in patients with chronic renalfailure. Guideline 8 : Administration of supplemental iron. Nephrol Dial Transplant, 1999, 14, S17-S18.22. BESARAB A, AMIN N, AHSAN M et al. Optimization of epoetin therapy with intravenous iron therapyin hemodialysis patients. J Am Soc Nephrol, 2000, 11, 530-538.23. KOOISTRA MP, NIEMANSVERDRIET EC, VAN ES A et al. Iron absorption in erythropoietin-treatedhaemodialysis patients : Effects of iron availability, inflammation and aluminum. Nephrol DialTransplant, 1998, 13, 82-88.24. WINGARD RL, PARKER RA, ISMAIL N et al. Efficacy of oral iron therapy in patients receiving recombinanthuman erythropoietin. Am J Kidney Dis, 1995, 25, 433-439.25. DOMRONGKITCHAIPORN S, JIRAKRANONT B, ATAMASTIKUL K et al. Indices of iron status in continuousambulatory peritoneal dialysis patients. Am J Kidney Dis, 1999, 34, 29-35.26. SHAVER MJ, GOLPER TA. Clinical applications of iron management in peritoneal dialysis patients.Seminars in Dialysis, 1999, 12, 257-261.27. MACDOUGALL IC, TUCKER B, THOMPSON J et al. A randomized controlled study of iron supplementationin patients treated with erythropoietin. Kidney Int, 1996, 50, 1694-1699.28. AHSAN N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia inperitoneal dialysis patients : a single center comparative study. J Am Soc Nephrol, 1998, 9, 664-668.29. YEE J, BESARAB A. Iron sucrose : the oldest iron therapy becomes new. Am J Kidney Dis, 2002,40, 1111-1121.30. KOSCH M, BAHNER U, BETTGER H et al. A randomized, controlled parallel-group trial on efficacyand safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treatedwith rHuEpo. Nephrol Dial Transplant, 2001, 16, 1239-1244.31. MACDOUGALL IC, CHANDLER G, ELSTON O et al. Beneficial effects of adopting an aggressive intravenousiron policy in a hemodialysis unit. Am J Kidney Dis, 1999, 34, S40-S46.32. CHANDLER G, HARCHOWAL J, MACDOUGALL IC. Intravenous iron sucrose : establishing a safe dose.Am J Kidney Dis, 2001, 38, 988-991.33. BESARAB A, KAISER JW, FRINAK S. A study of parenteral iron regimens in hemodialysis patients.Am J Kidney Dis, 1999, 34, 21-28.34. MACDOUGALL I, BAILIE G, RICHARDSON D et al. Worldwide safety profile of iron sucrose injection(Venofer ®) ) : Analysis of 1 004 477 patients from 1992 to 2001. J Am Soc Nephrol, 2002, 12, 333A.35. LUNDE N, PENNEL P, CHARYTAN C, et al. Safety of iron sucrose in the general hemodialysis population.J Am Soc Nephrol, 2001, 12, 359A-360A.36. NYVAD O, DANIELSEN H, MADSEN S. Intravenous iron-sucrose complex to reduce epoetin demandin dialysis patients. Lancet, 1994, 344, 1305-1306.37. ZAGER RA, JOHNSON AC, HANSON SY, et al. Parenteral iron formulations : a comparative toxicologicanalysis and mechanisms of cell injury. Am J Kidney Dis, 2002, 40, 90-103.38. GEISSER P, BAER M, SCHAUB E. Structure/histoxicity relationship of parenteral iron preparation.Arzneimittelforschung, 1992, 42, 1439-1452.39. LIM PS, WEI YH, YU YL, et al. Enhanced oxidative stress in haemodialysis patients receivingintravenous iron therapy. Nephrol Dial Transplant, 1999, 14, 2680-2687.40. CORTI MC, GAZIANO M, HENNEKENS CH. Iron status and risk of cardiovascular disease. AnnEpidemiol, 1997, 7, 62-68.
Page 3 and 4: TRAITEMENT MARTIAL DU PATIENT EN IN
Page 9: TRAITEMENT MARTIAL DU PATIENT EN IN

traitement martial du patient en insuffisance rénale chronique ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?